Zydus Cadila has received final approval from the US health regulator for Piroxicam capsules, used for the treatment of osteoarthritis and rheumatoid arthritis.
According to a BSE filing, Zydus Cadila will market Piroxicam Capsules USP in the strengths of 10 mg and 20 mg. The drug will be produced at the group’s manufacturing facility at SEZ, Ahmedabad.
The group has more than 209 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it had started filings in 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading down by 3.23 per cent at Rs 342.65 on the BSE.